Cognitive dysfunction is a recognized feature of mood disorders, including major depressive disorder (MDD) and bipolar disorder (BD). Cognitive impairment is associated with poor overall functional outcome and is therefore an important feature of illness to optimize for patients' occupational and academic outcomes. While generally people with BD appear to have a greater degree of cognitive impairment than those with MDD, direct comparisons of both patient groups within a single study are lacking. There are a number of methods for the assessment of cognitive function, but few are currently used in clinical practice. Current symptoms, past course of illness, clinical features, such as the presence of psychosis and comorbid conditions, may all influence cognitive function in mood disorders. Despite the general lack of assessment of cognitive function in clinical practice, clinicians are increasingly targeting cognitive symptoms as part of comprehensive treatment strategies. Novel pharmacological agents may improve cognitive function, but most studies of standard mood stabilizers, such as lithium and the anticonvulsants, have focused on whether or not the medications impair cognition. Non-pharmacological strategies, such as cognitive remediation and exercise, are increasingly studied in patients with mood disorders. Despite the growing interest in strategies to manage cognitive function, there is a paucity of high-quality trials examining either pharmacological or non-pharmacological modes of intervention.
Key words: bipolar, cognition, major depressive disorder, neuropsychological, treatment. C OGNITIVE DYSFUNCTION IS common in people with mood disorders. This overview first examines whether there are differences in cognitive function between patients with major depressive disorder (MDD) and those with bipolar disorder (BD). Following this, we examine three issues that are relevant to understanding cognitive dysfunction in patients with either MDD or BD: (i) assessment of cognitive dysfunction; (ii) factors that contribute to or protect against cognitive dysfunction; and (iii) treatment strategies targeted at improving cognitive function. We focus on recent investigations and meta-analyses.
COGNITIVE FUNCTION IN PATIENTS WITH MDD OR BD
Relatively few studies have compared the cognitive profile of individuals with BD and MDD, 1,2 and even fewer have compared euthymic patients from each diagnostic group. When effect sizes from studies of patients with BD are compared to those of studies of MDD, the degree of dysfunction appears to be greater in patients with BD. When patient groups are compared in the same study, however, extant data are conflicting. One early study found that remitted patients with MDD were more impaired than patients with BD. 3 In a study that compared patients with BD I, BD II and unipolar illness, all patient groups had some residual impairment in the remitted state but the patients with BD were not more impaired than those with MDD. 4 In a recent comparison of euthymic patients with BD and MDD, the patient groups did not differ from each other, although both groups differed from controls in several domains, including on tasks of attention and executive function. 5 The sample size of 25 participants in each patient group might not have been sufficient to detect subtle differences between diagnostic groups, however. 5 We found no significant differences in the performance of patients with BD compared to those with MDD, despite the fact that the sample size was relatively large (112 patients) and should have been able to detect any clinically significant differences between the groups (unpublished data).
In contrast, studies have reported that attention and inhibitory control deficits were most pronounced in the remitted patients who had been recently manic, 6 that remitted participants with BD have a specific executive deficit independent of attention impairment that is not apparent in patients with MDD, 7 and that participants with remitted BD are more impaired on tests of verbal memory, set-shifting, and inhibitory control, while patients with MDD are impaired on setshifting only. 8 A study of 205 participants found that patients with BD had widespread impairment compared to patients with MDD and the patients with BD were worse than those with MDD on measures of sustained attention and inhibitory control. 9 The study did not control, however, for pharmacological treatment or other variables.
A recent novel study examined cognition in over 140 000 participants in the UK Biobank cohort, extracting self-report data on MDD or BD. Participants in either diagnostic group differed only from controls in unadjusted analyses and when psychotropic medication use and current symptoms were controlled, there were few differences in measures of reasoning, reaction time and memory, 10 emphasizing the need for studies to control for related factors.
While there is therefore some evidence that patients with BD may have a greater degree of cognitive impairment than patients with MDD, studies that directly compare diagnostic groups have provided little definitive evidence for either qualitative or marked quantitative differences in cognitive function between the groups. Consistent with this notion, there appear to be few differences in patients' subjective experiences of cognitive dysfunction across the diagnostic groups.
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ASSESSING COGNITIVE FUNCTION IN PATIENTS WITH MOOD DISORDERS Current practice
A small study recently provided insight into the ways in which psychiatrists currently assess cognitive function. 12 In an online survey of 61 psychiatrists, a variety of measures were reported in routine clinical use. The most commonly used measures included the Mini Mental State Exam, the Clock Drawing Test and the Wechsler Memory Scale, none of which have been confirmed to be appropriate for detecting dysfunction in patients with mood disorders. Most were developed as screening agents for dementia. It is likely that the most common practice is to ask patients about their cognitive symptoms. 12 
Traditional neuropsychological tests
Given the overlap in reports of type and magnitude of deficit between diagnostic groups, it appears unlikely that standard neuropsychological measures can be reliably used as an adjunctive tool to reduce diagnostic uncertainty in patients with BD or MDD. A recent meta-analysis attempted to examine sensitivity of various cognitive measures in discriminating depressed participants from healthy participants. 13 Although the meta-analysis examined 22 studies, encompassed 955 patients and 7664 healthy participants, and examined a range of cognitive tests, the investigators were unable to identify tests with clear evidence of superior sensitivity in differentiating patients from comparison subjects. Another systematic review noted that there were over 150 measures reported in the literature to assess cognitive function in patients with mood or psychotic disorders; only 18% were deemed appropriate for use in the disease of interest. Of these, most had been used in studies of patients with psychotic disorders, with only one used in MDD and two used in BD. 14 While it is unlikely that any standard neuropsychological measures will subsequently be revealed to have demonstrably superior ability in detecting cognitive dysfunction in patients with mood disorders, adoption of a standard and generally accepted battery of measures that cover major cognitive domains may represent a significant advance in the field. Such an approach would at least increase the ease with which data can be aggregated across studies. Approaches such as those adopted by the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS), the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia (CNTRICS; http:// cntrics.ucdavis.edu/index.shtml) and the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia (CNTRACS; http://cntrics. ucdavis.edu/publications.shtml) may also be appropriate in mood disorders. The Brief Assessment of Cognition in Affective Disorder (BAC-A) has recently been proposed as a composite measure that includes assessment of memory, processing speed, working memory, reasoning, problem-solving, and affective processing. 15 It may allow for a standardized approach to the assessment of cognitive dysfunction. Given the heterogeneity in many previous reports regarding specific domains of cognition that are impaired in patients with mood disorders, a composite score reflecting multiple cognitive domains may be a useful way forward in research studies but the clinical utility of this approach remains to be determined.
Measures reflecting real-world function
There is also interest in extending assessment of cognition beyond the laboratory or clinical setting to understand the ways in which cognitive changes impact real-world function. In a recent study, for example, Peters and colleagues examined 'real-world executive dysfunction' as assessed by the Behavior Rating Inventory of Executive Functioning and the Frontal Systems Behavior Rating Scale, both selfreport scales. 16 Mood symptoms strongly predicted the severity of self-reported executive dysfunction, while comorbidity, chronicity, and medication load also influenced reports of executive dysfunction. One study reported a relation between functional outcome, depressive symptoms, and verbal memory. 17 This study did not report on the potential influence of deficits in other cognitive domains (although these were obtained in the patient sample), making it impossible to know whether verbal memory was simply a marker of poor cognitive function generally or whether the relation between symptoms, memory, and functional outcome was unique to verbal memory as a cognitive domain. Another study also found a relation between functional outcome as assessed by employment status and performance on a measure of sustained attention. 18 Bowie and colleagues also examined relations between functional outcome and cognition in patients with BD. 19 Another area of interest of relevance to real-world function is that of social cognition in patients with mood disorders and we have found that poor theory of mind is associated with lower reported levels of psychosocial function in patients with MDD and mild depressive symptoms 20 and in patients with BD. 21 In a systematic review of the neural basis underlying social cognition, we found an overall lack of inhibition by higher-order cognitive structures on limbic and emotion-related structures during social cognitive processing in patients with mood disorders. 22 
FACTORS THAT MAY INFLUENCE COGNITIVE FUNCTION IN PATIENTS WITH MOOD DISORDERS Onset of illness
Some people who are at risk of mood disorders have difficulty on some cognitive tasks when compared against age-and sex-matched controls. By the time of first illness onset, patients with MDD have measurable levels of cognitive dysfunction. 23, 24 In a meta-analysis of 15 studies that examined 644 firstepisode patients with MDD, deficits were noted in several cognitive domains. The average age in the meta-analytic sample was 39 years, however, which is older than the typical age of onset of MDD and raises questions about whether a portion of patients had previously unrecognized episodes. 23 There is evidence that first-episode patients with BD have detectable impairment in several cognitive domains. In one longitudinal study, patients had improvement in processing speed and executive function over the course of a year following diagnosis. 25 
Age of onset
A recent meta-analysis synthesized the evidence for cognitive dysfunction in pediatric BD. 26 One hundred twenty-four studies met criteria for inclusion, and in the aggregate, there was evidence for impairment in many of the same cognitive domains examined in adults with mood disorders. There is therefore, compelling evidence that cognitive dysfunction is not restricted to those with adult-onset illness. Amongst adults, however, a meta-analysis of 895 patients with MDD and 997 healthy participants from 27 studies reported that participants with late-onset illness had evidence of greater impairment in verbal memory, speed of information processing and some executive function. 27 There is also work in patients with MDD suggesting that cortical thickness may vary as a function of age of onset. 28 We found that patients with later onset of depression (average age about 50 years) had twice as many lifetime episodes of depression and had spent almost twice as long ill as those with earlyonset depression. Despite a lower burden of illness, participants with earlier onset of depression had more extensive cortical thinning than those with later-onset illness. 28 Whether changes in cortical thickness predicts cognitive function is not known.
Effect of symptoms and severity on cognitive function
In a review of 14 studies, performance on tasks of verbal memory, executive functioning, and processing speed, but not semantic fluency or visual spatial memory, was negatively associated with increasing symptom scores. 22 The presence of learning and memory deficits in patients with BD has been consistently reported in symptomatic and euthymic BD samples (see reviews and meta-analyses). [29] [30] [31] [32] [33] [34] A review of cognitive functioning in MDD patients found that verbal learning and memory deficits were among the domains most sensitive to clinical state: improvement in mood was associated with improvement in verbal learning and memory performance. 35 In contrast, Volkert and colleagues assessed patients with BD longitudinally across clinical states 36 and found that patients retained difficulty in working and verbal memory after entering remission. Thus, learning and memory deficits in MDD patients may be state-dependent, particularly subtle, or restricted to a subgroup of patients, such as those with extensive illness burden, 37 while the deficits may be longer lasting or indicative of a trait marker in BD.
Psychosis
The presence of psychotic symptoms is associated with greater impairment in visual spatial tasks, attention/working memory, psychomotor speed/ dexterity, executive function, and memory compared to patients without psychosis.
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Course of illness
Past illness burden may be a factor in predicting long-term cognitive outcome. Gorwood and colleagues examined verbal memory in a large sample of patients with MDD, both when they were acutely symptomatic and also when the acute depressive symptoms had abated. 41 Although the effect of past illness burden was not apparent when patients were acutely symptomatic, when re-tested after responding to treatment, patients with a larger number of past episodes were more impaired on the memory task.
A recent meta-analysis of patients with BD examined the longitudinal course of cognitive deficits over a meet test-retest interval of 4.6 years. 42 There was little evidence of cognitive decline in the measures assessed, but the authors were careful to identify a number of limitations in the reporting of raw data, which limited their ability to draw conclusions. Some of the noted limitations included the sensitivity of the cognitive tests to change, the inability to account for the possibility of critical time periods of illness (e.g., cognitive change might occur rapidly early in the course of illness but at a much slower rate [or not at all] later in the illness), problems with controlling for patients' mood state and pharmacological treatments at various assessment points, and the relatively short lengths of follow up. In another recent report, investigators found little evidence of progression of cognitive decline, but the sample was relatively small (70 patients in total). 43 Interestingly the authors suggest that cognitive problems might contribute to, rather than arise from, episodes. In a small number of patients with BD or MDD followed for 1 year, modest improvement was apparent, although there were persistent deficits. 44 Other investigators found that the degree of improvement following a first manic episode was partially accounted for by whether patients remained well during the follow-up intervel. 45 Examining specific cognitive domains, Lera-Miguel and colleagues found that processing speed and visual-motor skills normalized in a small sample of young people with BD over a 2-year follow up, while executive functioning, working memory, and verbal and visual memory remained impaired. 46 
Social and emotional context
We have reviewed the studies of emotion comprehension and theory of mind in patients with mood disorders. 47 Patients with mood disorders had enhanced activation in limbic and emotion-related structures and attenuated activity within frontal regions associated with emotion regulation and higher cognitive functions. We have also reviewed studies of emotional processing in patients with MDD. 48 Factors such as illness burden, symptom severity, comorbidity, medication status, and cognitive load may influence performance on tasks that require a high degree of social processing. 20 The extent to which deficits in social cognition may contribute to impaired social and occupational functioning requires further examination.
PHARMACOLOGICAL STRATEGIES FOR TREATING COGNITIVE DEFICITS IN MOOD DISORDERS Pharmacological interventions
While most treatments for mood disorders have relatively benign cognitive profiles, few have been demonstrated to be associated with cognitive benefit. Some, such as lithium, have been relatively extensively investigated for their negative cognitive profiles. A recent mega-analysis included data from 2876 participants with BD, from 31 primary studies 49 and reported that there was little evidence that medication exerted an effect on performance, although there was some evidence that being free of medication was associated with improved performance on two of 11 measures. One meta-analysis found that medication effects only the domain of processing speed in patients with BD. 33 Few studies have systematically examined the impact of polypharmacy on cognition in patients with mood disorders. There are recent overviews of agents that are being examined for possible benefit on cognitive symptoms; 50, 51 most are in the relatively early stages of evaluation.
Antidepressant medications
A small meta-analysis (three studies; n = 122) 52 found evidence for an improvement on one domain of executive functioning (Stroop test performance) during antidepressant treatment in patients with MDD without psychosis. These investigators also found meta-analytic support for improvement in executive function in patients treated for MDD. 52 A recent meta-analysis reported that in general, pharmacological therapies for MDD show some evidence for enhancing cognitive function. 53 There is, however, inconsistent support for this notion. 54 A recent study found benefit of a new antidepressant, vortioxetine, on cognition as a primary outcome in people with MDD. 55 This large trial (n = 642) found direct benefit of vortioxetine on a composite measure of cognition that included the digit-symbol substitution test and the Rey Auditory Verbal Learning Test.
Mood stabilizers
A meta-analysis that included 12 studies and 539 participants found that lithium is associated with small but significant deficits in immediate verbal learning, memory, and creativity. The metaanalysis did not detect impairment in delayed verbal memory, visual memory, attention, executive function, processing speed, or psychomotor performance. 56 In a carefully ascertained sample of patients with lithium-responsive BD compared to patients with comparable illness burden but minimal lifetime exposure to lithium, lithium-treated patients had longer reaction times on a measure of early information processing. 57 The groups did not differ notably on measures of verbal learning and memory.
Lamotrigine does not appear to impair cognition, although valproic acid, carbamazepine, and topiramate are associated with negative effects on cognition. 58, 59 Atypical antipsychotic medications may have negative effects on cognition compared to lithium and anticonvulsants. 58 
Stimulants
The use of stimulant medications in the treatment of MDD or bipolar depression has been reviewed. 60 In general, strong evidence for the use of stimulant medications in depression is lacking. There is little evidence for atomoxetine as an augmenting agent in depression. 61 Modafinil is recommended as a second-line choice for comorbid BD and ADHD 62 and may have a modest role as an augmenting agent in patients with depression. 63, 64 Acetylcholinesterase inhibitors Acetylcholinesterase inhibitors are indicated in patients with Alzheimer's disease but have been investigated in psychiatric disorders in a preliminary way. 65 Small, uncontrolled studies in patients with BD and MDD have been promising, but remain inconclusive. 59 We conducted a randomized, double-blinded, placebo-controlled pilot study of galantamine in MDD patients. 66 Galantaminetreated patients (n = 9) had numeric improvement on depression and cognitive measures compared to placebo-treated participants (n = 10), although the groups did not differ statistically. 66 Another doubleblind, placebo-controlled study of galantamine taken concurrently with electroconvulsive therapy reported cognitive improvement only for delayed memory. 67 
Intranasal insulin
In an innovative study, 62 participants with BD were randomized to adjunctive intra-nasal insulin or placebo for 8 weeks. A significant improvement versus placebo was noted with intranasal insulin therapy on executive function as assessed by the Trail Making Test-Part B. 68 This improvement was not related to changes in mood symptoms. Intranasal insulin was well tolerated with no significant adverse effects noted.
NON-PHARMACOLOGICAL STRATEGIES FOR TREATING COGNITIVE DEFICITS IN MOOD DISORDERS Cognitive remediation
Cognitive remediation typically involves training on mental processes and tasks. 69 A meta-analysis of seven studies (n = 104) of cognitive remediation in patients with mood disorders found a medium effect size (0.44) for pre/post cognitive change after training. 70 Another meta-analysis of nine randomized trials of patients with MDD found moderatelarge effects for attention, working memory, and global functioning. 71 We also found increases in brain activity as measured by functional neuroimaging after 10 weeks of cognitive training in 38 patients with mood disorders. 72 These increases were associated with improvement in measures of verbal working memory and delayed recall and were apparent in prefrontal, temporal, and parietal regions during working memory task and increased activations in the hippocampus in the recollection memory task after the training.
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A meta-analysis of cognitive rehabilitation in patients with various diagnoses also suggested that cognitive rehabilitation may have a role in patients with mood disorders. 70 We found some improvement in occupational functioning, consistent with another report of improved psychosocial and occupational functioning in an open trial of patients with BD 73 and a controlled trial of patients with MDD or BD. 74 A protocol for a randomized controlled trial of cognitive remediation in patients with BD and cognitive difficulties has been published. 75 
Exercise
Exercise may have positive effects on cognition in healthy people and is being investigated as a possible strategy for maintaining cognitive function throughout aging. It also improves symptoms of depression. [76] [77] [78] [79] The degree to which it actually improves cognitive function in those with a mood disorder is not well known. 80 High-dose exercise was associated with improvement in spatial working memory while other cognitive domains, including attention, visual memory, and spatial planning, improved regardless of dose in one study. 81 Another study included a subset of patients with BD (3/12, while the other participants had schizophrenia) and found that intense circuit training was associated with improvement in memory and processing speed; depressive symptoms also improved. 82 There are therefore a variety of factors that require investigation to understand how to maximize the benefits of exercise on cognition in patients with mood disorders. These include better understanding of the individual variability in response to training, optimal dosing or training schedules, the synergistic effects of exercise in combination with other interventions 83 and the actual mechanisms through which exercise works on the neural circuits that are disrupted in depression.
Supplements
Multiple studies report a protective role of erythrocyte membrane polyunsaturated fatty acids, in particular docosahexaenoic acid (DHA), against cognitive decline. 84 While few studies have specifically examined the relations between erythrocyte lipid composition and cognition in adults, deficiencies in Ω-3 polyunsaturated fatty acids, such as DHA, have adverse effects on cognition 85 while supplementation with Ω-3 polyunsaturated fatty acids may be beneficial to cognitive function. Polyunsaturated fatty acid supplementation may improve mood symptoms in patients with BD. 86 Whether cognitive function is also enhanced is unknown. In MDD, the evidence on cognition has been more mixed. Antypa and colleagues reported improved emotional decision-making in recovered individuals, 87 but no benefit was apparent in other cognitive domains in that study or in a randomized controlled trial conducted by Rogers and colleagues. 88 Vitamin D has been examined for its potential benefit in a number of conditions. A recent systematic review of vitamin D in adult patients with depression concluded that there was insufficient evidence to support the use of vitamin D in treating depressive symptoms. 89 Only one study of six included in the analysis included patients with depression 90 in which vitamin D was used as an augmentation agent in conjunction with fluoxetine. Furthermore, trials were often of short duration and did not uniformly include patients with vitamin D deficiency. Whether vitamin D might have measurable benefit in a subset of depressed patients with vitamin D deficiency is unknown and needs further investigation.
Stimulation therapies
Nadeau and colleagues examined whether repetitive transcranial magnetic stimulation (rTMS) therapy had an effect on various cognitive domains in patients with depression, reporting modest changes in performance following treatment. 91 There was evidence, however, that right hemisphere rTMS improved cognitive function, while left hemisphere rTMS had a negative impact on cognition. This effect was not reliant on the antidepressant effect of the treatment.
SUMMARY
The significance of cognitive symptoms associated with mood disorders has been recognized in the last decade or so. Studies have examined the nature of the impairment, the factors associated with the impairment and the effect of standard treatments on cognitive symptoms. There remain significant hurdles associated with translating the research findings into routine clinical assessment. Despite this, cognitive dysfunction is becoming a key target of treatment in its own right and future studies may confirm the optimal strategies -pharmacological and non-pharmacological -for managing this burdensome aspect of these illnesses.
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